A new meningococcal conjugate vaccine: What should physicians know and do?

Paediatrics and Child Health

Volumn 14, Issue 8, 2009, Pages 515-517

  Bortolussi, Robert ^a   Salvadori, Marina ^a  

^a NONE

Author keywords

Canada; MCV4; Meningococcal infection; Meningococcal vaccine

Indexed keywords

EID: 70449675014     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/14.8.515     Document Type: Short Survey

References (6)

1. Public Health Agency of Canada, National Advisory Committee on Immunization. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. Can Commun Dis Rep 2007;33(ACS-3):1-23. 〈http://www.phac-aspc. gc.ca/publicat/ccdr-rmtc/07vol33/acs-03/indexeng.php〉 (Version current at August 19, 2009).
2. Public Health Agency of Canada, National Advisory Committee on Immunization. Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. Can Commun Dis Rep 2009;36(ACS-3):1-39. 〈http://www.phac-aspc.gc.ca/publicat/ccdrrmtc/09vol35/acs-dcc-3/index-eng. php〉 (Version current at August 19, 2009).
3. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. [Principal author: S Halperin]. Meningococcal vaccine for children and adolescents. Paediatr Child Health 2005;10:405-406
4. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. [Principal author: R Bortolussi]. Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older - summary. Paediatr Child Health 2008;13:309.
5. Public Health Agency of Canada. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 2007;33:1-15. 〈http://www.phac-aspc.gc.ca/publicat/ccdr- rmtc/07vol33/dr3310a-eng.php〉 (Version current at August 19, 2009).
6. Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28:220-224